Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Capital Scarce, Charities Emerge As A Stronger Force On Start-Up Scene

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Disease charities are traditionally big funders of basic research. But those foundations are increasingly spawning specialized funds aimed at helping start-ups drive their candidates into later stages of development, where they might represent more attractive investment opportunities for pharmaceutical partners.

You may also be interested in...



Deals Of The Week Searches For Meaning In Deal Break-Ups

Amid a dearth of private-sector deals, we review some of this year’s break-ups, take a closer look at the Leukemia & Lymphoma Society’s deal-making strategy and highlight two deals from the U.K.’s Cancer Research Technology, as well as a licensing pact between Adimab and Alector.

Lpath, OptoSonics First To Win New Bridge Grants From NCI’s SBIR Center

The $3 million awards are designed to help companies attract support for the dicey period of transition from preclinical to Phase I.

Lpath, OptoSonics First To Win New Bridge Grants From NCI’s SBIR Center

The $3 million awards are designed to help companies attract support for the dicey period of transition from preclinical to Phase I.

Related Content

Topics

UsernamePublicRestriction

Register

PS004109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel